CDC28 protein kinase regulatory subunit 1B pseudogene 3Genealiases: []
Q-omics provides the consensus-scored CKS1BP3 profile across patient tissues and cancer cell-line models. CKS1BP3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CKS1BP3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CKS1BP3 RNA expression shows 14,268 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, HNSC, and BRCA as cancer lineages where CKS1BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKS1BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKS1BP3 survival associations across molecular data types. CKS1BP3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKS1BP3 RNA expression–survival associations across cancer types. High CKS1BP3 expression shows unfavorable associations in UVM, LIHC, KICH, UCEC and ACC, but favorable associations in COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for CKS1BP3 RNA expression.
This table summarizes CKS1BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CKS1BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKS1BP3 shows higher tumor expression in HNSC, LUAD, LUSC, STAD, BLCA and ESCA. The HNSC box plot shows higher CKS1BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.639, t-test p = .002).
This table shows molecular features associated with CKS1BP3 in patient tissues and cancer cell lines. In patient samples, CKS1BP3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
